You are here

Share:

Nanoparticle delivery of lung cancer therapeutic

Summary
The National Cancer Institute seeks parties interested in licensing or co-developing an improved treatment for non-small cell lung cancer based on inhalation of nano- and microparticle therapeutics.
NIH Reference Number
E-159-2014
Product Type
Keywords
  • NSCLC
  • non-small cell lung cancer
  • nanoparticle
  • immunotherapy
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in developed countries.  Despite the availability of several synergistic, targeted therapy regiments, the 5-year survival rate for NSCLC is only 15%.  The poor prognosis of NSCLS is due in part to limitations of current treatments, which do not trigger an immune response against NSCLC, nor can they be directly delivered into the lungs.  

Researchers at NCI’s Laboratory of Experimental Immunology have developed a novel method for synthesizing polyketal nanoparticles with adsorbed CpG oligonucleotides (NP-CpG) that possess immunomodulatory and potent anti-tumor activity, and can be safely delivered to the lungs. The researchers have demonstrated a link between NP-CpG accumulation in pulmonary tumors and an increase in TH1 cells and decrease in Treg cells in vivo.  They have optimized particle size for intratracheal delivery, and in vivo studies showed improved efficacy, PK, and PD compared to other CpG formulations. The novel NP-CpG preparation can be made reproducibly and to scale for expanded in vivo studies. 

The NCI seeks partners interested in licensing or collaborative research to co-develop this therapeutic with an initial goal of preclinical evaluation leading to clinical testing.

Potential Commercial Applications
  • Adjuvant or synergistic therapeutic to enhance efficacy of existing treatment regimes for NSCLC
Competitive Advantages
  • Optimized particle size for intratracheal delivery
  • Improved efficacy, PK, and PD compared to other CpG formulations
Development Stage
Publications

Klinman D, et al. [PMID 18430787]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/024,657, Filed 15 Jul 2014
Therapeutic Area
Updated
Wednesday, December 20, 2017